approved by FDA for mild Alzheimer’s disease: uncertain as to which patients may benefit A recombinant monoclonal antibody reduce amyloid plaque on pet imaging Coverage: not covered by public & private payers Cost: about $60,000 per year, depends on weight inconsistant clinical effects on rating scales Dosing MRI brain...